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Abstract
Granulocyte-colony stimulating factor (G-CSF) improves outcome after experimental SCI by counteracting apoptosis, and
enhancing connectivity in the injured spinal cord. Previously we have employed the mouse hemisection SCI model and
studied motor function after subcutaneous or transgenic delivery of the protein. To further broaden confidence in animal
efficacy data we sought to determine efficacy in a different model and a different species. Here we investigated the effects
of G-CSF in Wistar rats using the New York University Impactor. In this model, corroborating our previous data, rats treated
subcutaneously with G-CSF over 2 weeks show significant improvement of motor function.
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Introduction
To date there are only very limited treatment options available
to improve consequences of spinal cord injuries (SCI) apart from
primary surgical intervention for stabilization and decompression
and later rehabilitation training. Few pharmacological therapies
are currently being evaluated clinically. Given the young age of
patients affected by SCI, and the considerable impairment in daily
living activities, there is a high need for a treatment that is able to
partially restore motor functions to raise the quality of everyday
life.
We have shown before that the G-CSF receptor is expressed by
neurons in the brain [1] and that G-CSF induces several pathways
in neurons to protect against apoptotic cell death. Systemically
applied G-CSF passes the intact blood–brain barrier [1,2]. In
stroke models in rodents G-CSF decreases infarct size, and
improves functional recovery. Furthermore there is evidence for
therapeutic activity in chronic neurodegenerative diseases [3–5].
We could recently demonstrate efficacy of G-CSF in a mouse
model for spinal cord injury using both subcutaneous and
transgenic delivery of the protein [6].
In order to broaden confidence in efficacy of G-CSF in
experimental SCI models, we aimed to confirm experimental data
gained in one animal species in a second one. In addition,
choosing a different experimental disease model should help to
uncover false positive treatment effects based on specific
characteristics of one model. Previously, we observed improve-
ment of motor function in a model of partial transection of the
spinal cord after treatment with G-CSF in mice. In this study we
used Wistar rats and an experimental SCI where trauma is
induced by the New York University (NYU) Impactor device.
Instead of directly transsecting the spinal cord, the tissue is
damaged by a weight drop. The impact of the weight onto the
surface of the spinal cord leaves the dura intact and leads to an
acceleration of the spinal cord tissue comparable to the situation in
an accident were the spinal column is rapidly bent. These strong
forces act on the long projecting fibres in the spinal cord with the
potential consequence of rupture. The impactor model is viewed
by many as the best SCI model since it mimicks events occurring
during trauma in the human.
Results
Conduction of the model
Ten animals received only the laminectomy but no impact
(surgery control; n=10). 51 animals were subjected to the weight
drop model using the NYU impactor [7,8]. This was done to
ensure that the paralysis seen in the impactor-injury-group was not
the result of the surgery procedure itself. All sham-operated
animals showed no sign of motor impairment. 2 animals were
excluded from the study due to irregular impact curves. This left
24 animals treated with G-CSF, and 25 with vehicle.
The mean compression rate, calculated by dividing the
compression depth by the difference in time between initial spinal
cord contact and reversal of the rod (deepest dipping point of the
impactor rod), was 0.57560.0051 m/s in the untreated group and
0.58760.0057 m/s in the treated group. There was a trend for a
higher compression rate in the treated group, the difference
between the groups was however not significant (ttest p=0.12).
The compression rate is a measure for the acceleration of the tissue
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fibers. The higher the compression rate, the more the tissue is
damaged.
The duration of the surgery before the weight drop injury is an
important source of variation in this model. The main reason for
delays during surgery is difffuse bleeding following laminectomy
that has to be stopped before the impact is delivered. The mean
time until impact (mean=64.6260.80 min for the untreated
group, 64.6060.86 min for the treated group) was identical for the
two groups (ttest p=0.99). Treatment started immediately after
injury with an IV-bolus of 60 mg G-CSF or vehicle per kg
bodyweight via a jugular catheter. Subcutaneous minipumps were
implanted dorsally and continuously released 30 mg G-CSF/kg
bodyweight/day or vehicle over 2 weeks. This treatment scheme
was chosen because of the limited plasma half-life of G-CSF
(,4 h).
Outcome analysis
Six animals died before the observation period was completed,
three in the G-CSF group and three in the vehicle group. This left
n=21 animals in the G-CSF group, and n=22 animals in the
vehicle group for which data until day 35 were available. The
primary pre-specified analysis of the data includes all animals (G-
CSF: n=24; vehicle: n=25), and uses the standard procedure last-
observation-carried-forward (LOCF) for replacement of missing
values.
The Basso-Beattie-Bresnahan score (BBB score) rates the motor
abilities of the hindlimbs from 0=no movement to 21=normal
movement [9]. A BBB score of 9 and above indicates weight
supported steps. The mean BBB scores in the untreated group
were 0.1960.06 (day 1), 3.4860.56 (day 7), 6.4860.62 (day 14),
7.5660.52 (day 21), 7.8760.55 (day 28) and 8.0060.70 (day 35)
compared to 0.2660.09 (day 1), 3.7860.58 (day 7), 8.3560.79
(day 14), 9.6660.77 (day 21), 10.3160.88 (day 28) and
10.5060.90 (day 35) in the treated group (Figure 1A). There is
a significant difference between the two groups with a positive
influence of G-CSF treatment on the motor behaviour of the
animals (p,0.05 for factor treatment,p ,0.005 for interaction
treatment*time (days after injury) by linear regression analysis).
Omitting animals that died before the end of the test series and
removing all imputed (LOCF) values did not change this effect.
The Grid Walk test requires advanced motor abilities and
animals with less than 16 errors are already well recovered. We
observed a significant difference between the two groups with a
positive influence of G-CSF treatment on the motor behaviour of
the animals (Figure 1B;p ,0.05 for factor treatment,p ,0.005 for
interaction treatment*time (days after injury) by linear regression
analysis). Again, omitting dead animals and removing LOCF
values had no considerable effect on interpretation of the outcome.
In the Swim Test the animals are moving in a narrow water
basin of 1 m length. A ladder at the opposite end motivates the
animals to cross the basin. The hindlegs are analyzed and rated
from 0 (no movement) to 10 (normal movement). Although there is
a visible trend towards better performance (Figure 1C) this
difference failed significance.
Discussion
This study aimed to confirm evidence for efficacy of G-CSF in
the treatment of SCI originally obtained in a mouse transection
model in a different species with a different injury model [6]. The
weight drop model in rats showed clearly beneficial effects of G-
CSF treatment for the main motor outcome parameters BBB and
Grid Walk. No significant change between groups could be
detected for the Swim Score, a test that certainly has less statistical
power in SCI models as also observed previously [6]. Post-hoc
analyses of our data revealed a power of only 18% to detect a 25%
difference in means.
Here, we demonstrated for the first time the beneficial effects of
G-CSF in a spinal cord contusion model in the rat using the NYU
Figure 1. Outcome analysis in rats subjected to weight drop.
(A) Mean BBB scores in untreated (2) and G-CSF-treated (+) rats from 1
to 35 days, including all data (LOCF) (n=24 for G-CSF treatment, n=25
for vehicle treatment; p,0.05 for factor treatment,p ,0.005 for
interaction treatment*time (days after injury) by linear regression
analysis). (B) Mean Grid Walk scores in untreated (2) and G-CSF-treated
(+) rats from 7 to 35 days, including all data (LOCF) (p,0.05 for factor
treatment,p ,0.005 for interaction treatment*time (days after injury) by
linear regression analysis). (C) Mean Swim Test scores in untreated (2)
and G-CSF-treated (+) rats after 7 to 35 days, including all data (LOCF).
Data is represented as mean 6 SEM. This test.
doi:10.1371/journal.pone.0029880.g001
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appears currently as the best contusion model available [8], and
has been judged as very similar to the pathophysiology of human
spinal cord contusion injuries in a systematic comparison [7]. The
induced motor deficit in the impactor model is also more severe
than injury induced by partial spinal cord dissection, and the
amount of recovery does not seem as big here as in our previous
studies [6]. In the absence of any successful SCI therapy in man it
is always difficult to judge the meaning of an effect size in animal
models. Although the grid walk score appears as a highly
continuous linear scale this score suffers from a lower border
ceiling effect lacking discriminatory sensitivity (all animals after
SCI models start out with 20 errors), and a limited factual range:
To reach a value of 16 errors the animals have to be already well
recovered. The true range of this score is therefore far more
limited than a true linear range of 0–20. In the important
functional BBB score there is a relative increase in performance by
25%, which appears substantial also with regard to possible
translations of this therapy to humans.
A number of other labs has performed spinal cord injury and
ischemia models with G-CSF treatment alone, or in combination
or control group with some sort of cellular transplantation therapy
[6,10–15]. Table 1 lists all published data on G-CSF treatment
approaches in SCI models. All studies have been performed in
either mice or rats. Two groups have used compression models,
two groups used transection models, static contusion was used by
one group, and one group has employed an ischemic model.
Treatment duration was between one and 14 days. Drug
application modes were subcutaneous, intrathecal, or intravenous.
Doses given ranged from 50 mg/kg bodyweight up to 300 mg/kg
bodyweight, with one group using 10 mg G-CSF for intrathecal
injections without bodyweight adjustment. All groups report
functional outcome in the animals, with 5 publications reporting
the BBB score. Two groups used combination therapy with stem
cells (neural stem cells [14] or bone marrow derived cells [10]), one
group used a combination with stem cell factor [15], the four other
publications use G-CSF only [6,11–13], Urdzikova et al. use a G-
CSF only control group in addition to bone marrow stem cell
combination [10].
The mechanisms that are discussed as being responsible for the
beneficial effect of G-CSF are induced proliferation of oligoden-
droglial precursors [15], inhibition of apoptotic cell death via
activation of protective pathways (Akt, ERK, stat3 – Bcl2 - Bcl-Xl)
[6,11,12], suppression of excitotoxicity [13], support for stem cells
[10,14], and an influence on neuronal plasticity and spinal cord
tract connectivity [6]. This multimodal activity of G-CSF indeed is
a principal argument for increased success probability in the clinic
as opposed to singular approaches as has also been discussed in the
stroke field [16].
All SCI studies cited above report improved functional recovery
following G-CSF therapy. We are the first here to report
functional improvement after G-CSF treatment in the impactor
model, often regarded as the likely most relevant model for
traumatic spinal cord injury. Together these are 8 reports on
activity of this growth factor in various models, and from different
labs. Together with the data from our lab this forms a credible
body of evidence that G-CSF has a robust effect in SCI in different
models and species. High doses of G-CSF appear safe in acute
neurological disease in man [17]. G-CSF is therefore a candidate
drug for spinal cord injury therapy that can be rapidly translated
into the clinic.
Materials and Methods
Ethics statement
All animal experiments were conducted in agreement with
national and international guidelines. Care was taken to minimize
suffering for the animals. Over the entire observation period
animals received Tramadol (Tramal-ratiopharmH (Ratiopharm
GmbH), added to drinking water, 15 mg/kg BW/d) in the
drinking water for pain management. Animal experiments were
approved by the Regierungspra ¨sidium Karlsruhe (AZ 35-
9185.81/G-15/05).
Experimental SCI by weight drop
Wistar rats were provided by Charles River Laboratories.
Acclimatization was done for 1 week before starting the study.
Animals were housed using standard procedures with normal
light-dark periods. Special care was taken to allow adequate access
to food and water during the trial. Female rats of ,300 g (app. 2
months of age) were anesthetized by inhalation of 70% N2O, 30%
O2 and 1% Halothane. Laminectomy was performed at spinal
Table 1. Listed are the different spinal cord injury models in rodents where G-CSF demonstrated beneficial effects.
SCI models Species Application mode and treatment duration
Outcomes and behavioural
testing References
Balloon induced
compression
rat +/2 combination bone marrow stem cells
and i.v. 50 mg/kg bodyweight/day; 5 days
+functional outcome; BBB and
plantar test
Urdzikova et al., 2006
Compression mice s.c. 200 mg/kg bodyweight/day; 5 days +functional outcome;motor
function scale
Nishio et. al, 2007
Spinal cord ischemia rat i.t. 10 mg ;1d a y +functional outcome; MDI Chen et al., 2008
Spinal cord ischemia rat i.t.10 mg; 1day +functional outcome, BBB Chen et al., 2010
Transection rat Combined NSC+ s.c. G-CSF 50 mg/kg
bodyweight/day; 5 days
+functional outcome; BBB Pan et al., 2008
Static contusion mice Combined SCF and s.c. G-CSF 300 mg/kg
bodyweight/day; 10days
+functional outcome, BBB LRS Osada et al., 2010
Transection mice i.v. 60 mg/kg bodyweight; 1day and s.c.
30 mg/kg bodyweight; 14 days
+functional outcome; BBB, swim
test and grip walk
Pitzer et al., 2010
Given are the respective spinal cord injury models, the animal species, the application mode and the outcome of the experiment with the behavioural testings used (+:
significant benefit; s.c. subcutaneously; i.v. intravenously; i.t. intrathecally; NSC: neural stem cells; SCF: Stem Cell Factor; MDI: Motor Deficit Index; BBB: Basso, Beattie and
Bresnahan locomotor score).
doi:10.1371/journal.pone.0029880.t001
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25 mm height onto the exposed spinal cord with intact dura. The
weight drop was performed with the help of the NYU (MASCIS)
Impactor directly obtained from Dr. Wise Young, Rutgers
University, New York. Every impact and the resulting forces on
the tissue were monitored and documented on-line to control for
uniform severity of the injury. The animals were monitored daily
for signs of stress, pain, decubitus, autophagia, autotomia, or
dehydration. The bladder was emptied manually twice per day
(Crede ´ maneuver); the first week after the surgery animals received
Cotrimoxazol (Cotrim-ratiopharmH (Ratiopharm GmbH), solu-
tion for IP-injection 50 mg/kg BW/d, diluted in Ringer)) to
prevent urinary tract infections. Over the entire observation
period animals received Tramadol (Tramal-ratiopharmH (Ratio-
pharm GmbH), added to drinking water, 15 mg/kg BW/d) in the
drinking water for pain management.
Treatment
The treatment started immediately after injury with an IV-bolus
of 60 mg G-CSF (Filgrastim 30 MU/ml) or vehicle/kg BW via a
jugular catheter. Vehicle and the G-CSF buffer solution consisted
of 10 mmol/L HAc/NaAc, pH 4.0, 250 mmol/L Sorbitol,
0.004% (v/v) Tween-80. In addition, an osmotic minipump (Alzet
2002) was implanted subcutaneously delivering 30 mg/kg G-CSF
BW/day for 14 days or vehicle.
Behavioural assessment
The animals’ motor behavior was monitored weekly for 5 weeks
postinjury. All behavioral tests were recorded with a video camera
and scored independently by two observers blinded to the treatment.
BBB locomotor score. The general locomotor performance
of the animals was assessed using the BBB locomotor rating scale
with slight modifications [9]. In brief, rats were placed on a
runway of 1.2 m length and 10 cm width on top of an inclined
mirror (60u angle) to facilitate the observation of hind-limb
movements. Hindlimb locomotion was scored from 0 (for no
observable hindlimb movement) to 21 points (regular movement).
Every animal had to cross the runway three times. The BBB test
was performed in weekly intervals and at day 1 after SCI.
Grid walk test. Deficits in descending motor control were
examined by assessing the ability to navigate across a 1.2 m long
runway with irregularly spaced metal bars and gaps of 0.5–2 cm
[18]. A defined 10-bar-sector was chosen for the analysis. To
prevent habituation to a fixed bar distance, the bars in this sector
were changed for each testing session. The performance was
scored by counting the number of errors in foot placement per 20
steps (10 for each foot). If the animal was unable to use its
hindlimbs for weight support, it made two errors per bar resulting
in a total of 20 errors. When the hindlimb paw was not accurately
placed on the bar, this was counted as error. Any misplacement of
the paw, any slippage between rungs was counted as error. To
perform well on this test animals must show advanced motor-
sensory abilities, and have to have weight supported. Spastic
movements of the hindlimb are not considered an improvement
and can be clearly distinguished from correct plantar placement.
Uninjured control animals usually made no or very few mistakes.
Thegrid walktest wasperformed once a week for5 weeks afterSCI.
Swimming score. A swimming test was used to determine
the locomotor performance of injured rats in absence of cutaneous
and proprioceptive sensory input from the hindlimbs. The animals
had to swim in a 1.2 m long and 10 cm wide water tank.
Swimming performance was evaluated by scoring the following
features: hindlimb movement, hindlimb-forelimb coordination,
tail position, paw position and lateral stability. Uninjured rats
received 10 points, while completely paraplegic animals scored
0 points as previously described [19]. A detailed scoring protocol is
available as Table S1. Each rat had to cross the tank twice. The
swimming test was performed weekly for 5 weeks after SCI.
Statistics
All experiments were conducted in a completely randomized
and blinded fashion using computer-generated probe allocation,
and separation of experiment conduction from data analyses.
Statistical analyses were done using JMP 8.01 (SAS Institute). Data
analyses were performed as closely as possible to clinical trial
standards (adhering to the International Conference on Harmo-
nization (ICH) E9 guideline where applicable), entering all animals
that had received treatment and where at least one behavioural
data point was available into the analysis according to the Full
Analysis Set (FAS) definition. If an animal did not survive the full
observation period, the last observed score was carried forward
(LOCF). In secondary analyses we also performed all analyses with
omission of missing values. For comparison of two groups, t-test
statistics was used. For time series of measurements linear
regression analysis was performed using time, treatment, the
interaction of both as factors, and animal identity as random
effect. P-values of ,0.05 were regarded as statistically significant.
Values are given as mean6SEM.
Supporting Information
Table S1 Swimming Score. The swimming performance of
the rat was evaluated by scoring the following features: hindlimb
movements, hindlimb-forelimb coordination, tail position, paw
position, sagittal and coronal balance. Scoring scales are added
and maximal reached scale is 10.
(PDF)
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